Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
☩Howard Morris Australia
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
☩Jill Tate Australia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada


Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Arianna Lucini Paioni
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it



Area soci
Non possiedi o non ricordi la password!
Clicca qui

BC: Articoli scritti da M.T. Sandri

“The recognition and initial management of ovarian cancer”: un’analisi commentata del documento preparato dal National Institute for Health and Clinical Excellence (NICE)
The recognition and initial management of ovarian cancer: a commented analysis of the document prepared by the National Institute for Health and Clinical Excellence (NICE)
<p>The document &quot;Ovarian cancer: the&nbsp;recognition and initial management of ovarian cancer&quot; is a guideline issued in April 2011 by NICE, which revises a&nbsp;number of clinical issues related to the diagnosis and initial management of ovarian cancer. For this purpose, several&nbsp;databases were used, carrying out the work between April 2009 and July 2010, and then updating the guideline with&nbsp;data from the literature published before July 16, 2010. NICE clinical guidelines are based on the best available&nbsp;evidence of clinical and cost effectiveness and are produced to help professionals and patients make informed&nbsp;choices about appropriate healthcare. In this document, we translated the most salient parts of the guideline, relating&nbsp;to the chapters entitled &quot;Detection in primary care&quot; and &quot;Establishing the diagnosis in secondary care&quot;, integrated by&nbsp;some comments in order to contextualize and discuss the use of this guideline in daily clinical practice.</p>
Biochimica Clinica ; 37(3) 220-228
Documenti - Documents
 
Biomarcatori del carcinoma della prostata: la caccia è sempre aperta
Biomarkers for prostate cancer: the hunt is still open
Biochimica Clinica ; 35(5) 353
EDITORIALE - EDITORIALE